Intravenous ceftriaxone, followed by 12 or three months of oral treatment with trimethoprim-sulfamethoxazole in Whipple's disease.

BACKGROUND There is no agreement on how and for how long Whipple's disease should be treated. In a randomized trial it was shown that patients can be cured with ceftriaxone or meropenem followed by trimethoprim-sulfamethoxazole for 12 months. The present study tested whether trimethoprim-sulfamethoxazole for three months is sufficient. METHODS In the time from July 2004 to July 2008, 40 untreated patients from central Europe were sequentially admitted to an open-label, non-randomized extension of the previous trial with essentially an identical protocol. The modified treatment consisted of 2 g ceftriaxone intravenously once daily for 14 days followed by oral trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 months. Primary endpoint was treatment efficacy compared with the previous study. RESULTS Twelve months of treatment with trimethoprim-sulfamethoxazole was not more effective than 3 months as indicated by clinical findings, laboratory (p = 0.405, p = 0.631, resp.), and histological data (p = 0.456). 36 of 37 surviving patients including 14 with cerebrospinal infection were in remission without evidence of recurrence after a median follow-up time of 80 months. In one patient, Tropheryma whipplei arthritis recurred 63 months after initial therapy. Secondary endpoints indicate that histology of intestinal biopsies was a more useful indicator to determine eradication of T. whipplei than PCR. In submucosal and extra-intestinal tissue, the diagnostic value of the PCR was superior. Prospective data disclosed a heterogeneous spectrum of clinical presentation and course of Whipple's disease. CONCLUSION This study indicates that ceftriaxone followed by three months of trimethoprim-sulfamethoxazole is highly efficacious in the treatment of Whipple's disease.

[1]  C. Loddenkemper,et al.  The Immune Reconstitution Inflammatory Syndrome in Whipple Disease , 2010, Annals of Internal Medicine.

[2]  E. Crosetti,et al.  Short-term antibiotic treatment in Whipple's disease. , 1991, Journal of clinical gastroenterology.

[3]  C. Poyart,et al.  Whipple's disease: acquired resistance to trimethoprim-sulfamethoxazole , 2000, American Journal of Gastroenterology.

[4]  F. Fenollar,et al.  Whipple's disease. , 2007, The New England journal of medicine.

[5]  D. Raoult,et al.  Resistance to trimethoprim/sulfamethoxazole and Tropheryma whipplei. , 2009, International journal of antimicrobial agents.

[6]  C. Loddenkemper,et al.  Whipple's disease: new aspects of pathogenesis and treatment. , 2008, The Lancet. Infectious diseases.

[7]  D. Raoult,et al.  Evidence of lifetime susceptibility to Tropheryma whipplei in patients with Whipple's disease. , 2011, The Journal of antimicrobial chemotherapy.

[8]  D. Raoult,et al.  Prevalence of asymptomatic Tropheryma whipplei carriage among humans and nonhuman primates. , 2008, The Journal of infectious diseases.

[9]  D. Raoult,et al.  Infection: How should classic Whipple disease be managed? , 2010, Nature Reviews Gastroenterology &Hepatology.

[10]  D. Raoult,et al.  Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium. , 2005, The Journal of antimicrobial chemotherapy.

[11]  M. Maiwald,et al.  Diagnostic application of a polymerase chain reaction assay for the Whipple's disease bacterium to intestinal biopsies. , 1996, Gastroenterology.

[12]  G. Feurle,et al.  Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. , 2010, Gastroenterology.

[13]  H. Otto,et al.  Histology of intestinal whipple's disease revisited , 1996, Virchows Archiv.

[14]  J. Sahel,et al.  Whipple's disease: immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. , 2003, Human pathology.

[15]  D. Raoult,et al.  The combination of chloroquine and minocycline, a therapeutic option in cerebrospinal infection of Whipple's disease refractory to treatment with ceftriaxone, meropenem and co-trimoxazole. , 2012, The Journal of antimicrobial chemotherapy.

[16]  D. Raoult,et al.  Acquired resistance to trimethoprim-sulfamethoxazole during Whipple disease and expression of the causative target gene. , 2008, The Journal of infectious diseases.